These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9610690)

  • 1. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
    Taniguchi K; Yonemura Y; Nojima N; Hirono Y; Fushida S; Fujimura T; Miwa K; Endo Y; Yamamoto H; Watanabe H
    Cancer; 1998 Jun; 82(11):2112-22. PubMed ID: 9610690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
    Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M
    Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma.
    Endo K; Shirai A; Furukawa M; Yoshizaki T
    Hum Pathol; 2006 Aug; 37(8):1111-6. PubMed ID: 16867875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
    Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
    Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
    Zhang L; Zhao ZS; Ru GQ; Ma J
    World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
    Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y
    J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target.
    Oh HA; Lee G; Kang HJ; Kim YG; Bae SH; Lee JL; Lee KH; Hyun MS; Kim DS
    Cancer Res Treat; 2003 Feb; 35(1):9-15. PubMed ID: 26680909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.
    Huang Z; Zhang N; Zha L; Mao HC; Chen X; Xiang JF; Zhang H; Wang ZW
    Asian Pac J Cancer Prev; 2014; 15(2):989-97. PubMed ID: 24568530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
    Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ
    Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic significance of expression of c-met oncogene and its relation to gastric mucosal lesions].
    Zhuang X; Zheng J; Lin S; Sun G; Li Y
    Zhonghua Bing Li Xue Za Zhi; 2000 Dec; 29(6):409-11. PubMed ID: 11866940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
    Yonemura Y; Nojima N; Kawamura T; Ajisaka H; Taniguchi K; Fujimura T; Fujita H; Bandou E; Fushida S; Endou Y; Obata T; Sasaki T
    Oncol Rep; 1997; 4(6):1229-34. PubMed ID: 21590227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
    Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
    J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
    Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
    J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.